Mechanisms Involved in the Antiplatelet Activity of Ketamine in Human PlateletsChang Y.a,d · Chen T.L.b · Wu G.J.a · Hsiao G.c · Shen M.Y.d · Lin K.H.d · Chou D.S.c · Lin C.H.d · Sheu J.R.c,d
aDepartment of Anesthesiology, Shin Kong Wu Ho-Su Memorial Hospital, and Departments of bAnesthesiology and cPharmacology, and dGraduate Institute of Medical Sciences, Taipei Medical University, Taipei, Taiwan, ROC J Biomed Sci 2004;11:764–772 (DOI:10.1159/000081823)
The aim of this study was to systematically examine the inhibitory mechanisms of ketamine in platelet aggregation. In this study, ketamine concentration-dependently (100–350 µM) inhibited platelet aggregation both in washed human platelet suspensions and platelet-rich plasma stimulated by agonists. Ketamine inhibited phosphoinositide breakdown and intracellular Ca2+ mobilization in human platelets stimulated by collagen. Ketamine (200 and 350 µM) significantly inhibited thromboxane (Tx) A2 formation stimulated by collagen. Moreover, ketamine (200 and 350 µM) increased the fluorescence of platelet membranes tagged with diphenylhexatriene. Rapid phosphorylation of a platelet protein of Mr 47,000 (P47), a marker of protein kinase C activation, was triggered by phorbol-12,13-dibutyrate (100 nM). This phosphorylation was markedly inhibited by ketamine (350 µM). These results indicate that the antiplatelet activity of ketamine may be involved in the following pathways. Ketamine may change platelet membrane fluidity, with a resultant influence on activation of phospholipase C, and subsequent inhibition of phosphoinositide breakdown and phosphorylation of P47, thereby leading to inhibition of intracellular Ca2+ mobilization and TxA2 formation, ultimately resulting in inhibition of platelet aggregation.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50